Duchenne Research Fund
  • Home
  • Duchenne facts
  • Our story
  • Our projects
  • News
  • Get involved
    • Get involved
    • Gallery
  • Contact
  • Donate
Select Page

Solid to acquire AavantiBio and focus on next-generation gene therapy candidate

3 Oct 2022

Solid Biosciences has announced its entry into a definitive merger agreement to acquire AavantiBio, to create a genetic medicines company focused on neuromuscular and cardiac rare diseases, maintaining a strong focus on Duchenne. In a letter to the Duchenne community,...

Most recent:

  • Duchenne Care UK podcast series launched
  • Duchenne Care UK orthopaedic guideline recognised by NICE
  • Landmark day for Duchenne as Givinostat approved for use in England
  • Solid doses first patient on Phase 3 trial
  • Duchenne Care UK launches psychosocial guidelines

More about our projects:

administrative post award clinical post complementary current drug development early stage facility gene therapy past post project research standards of care

Jump to:

  • Donate
  • Contact Us
  • Get involved
  • Gallery
  • Our projects
  • Our story
  • Privacy
  • Home
  • Donate
  • Contact Us
  • Get involved
  • Gallery
  • Our projects
  • Our story
  • Privacy
  • Home
  • Facebook
  • Twitter
  • Instagram
Copyright © 2026 The Duchenne Research Fund. Registered Charity No. 1119068. Website by Sheli Rodney